The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor–directed therapy.1
Review the story here: https://www.onclive.com/view/fda-grants-full-approval-to-rucaparib-for-brca-mutation-associated-mcrpc